dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Moore, Kathleen N |
dc.contributor.author | Oza, Amit M. |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Lorusso, Domenica |
dc.contributor.author | Scambia, Giovanni |
dc.contributor.author | Colombo, Nicoletta |
dc.date.accessioned | 2022-06-13T09:49:45Z |
dc.date.available | 2022-06-13T09:49:45Z |
dc.date.issued | 2021-06 |
dc.identifier.citation | Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757–65. |
dc.identifier.issn | 0923-7534 |
dc.identifier.uri | https://hdl.handle.net/11351/7663 |
dc.description | Quimioteràpia; Mirvetuximab soravtansina; Càncer d'ovaris |
dc.description.sponsorship | This work was supported by ImmunoGen, Inc (no grant number). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Annals of Oncology;32(6) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Ovaris - Càncer - Tractament |
dc.subject | Immunoglobulines - Ús terapèutic |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Ovarian Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Immunoconjugates |
dc.subject.mesh | /therapeutic use |
dc.title | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.annonc.2021.02.017 |
dc.subject.decs | neoplasias ováricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inmunoconjugados |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1016/j.annonc.2021.02.017 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Moore KN] Department of Obstetrics and Gynecology, Stephenson Cancer Center/University of Oklahoma Health Sciences Center, Oklahoma City, USA. [Oza AM] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. [Colombo N] Department of Gynecologic Oncology, European Institute of Oncology IRCCS. University of Milan-Bicocca, Milan, Italy. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Scambia G] Gynecology Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS Roma, Rome, Italy. [Lorusso D] Gynecologic Oncology, Fondazione IRCCS National Cancer Institute, Milan, Italy |
dc.identifier.pmid | 33667670 |
dc.identifier.wos | 000648935000009 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |